METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy targets multiple cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for Hard-to-Treat breast cancer: Two-Drug cocktail shows promise
Disease control Recruiting nowThis study is for people with metastatic triple-negative breast cancer that has not responded to one prior treatment. It tests two combinations of drugs: one with sacituzumab govitecan and nivolumab, and another that adds a third drug, relatlimab. The goal is to see which combina…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug duo takes on tough breast cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs, naxitamab and sacituzumab govitecan, is safe and effective for people with metastatic triple-negative breast cancer. The study aims to find the best dose and check for side effects in 31 adults whose cancer has spread…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental cocktail aims to outsmart Hard-to-Treat breast cancer
Disease control Recruiting nowThis early-phase trial is testing a new combination of three drugs—cyclophosphamide, axatilimab, and retifanlimab—in people with metastatic triple negative breast cancer that has stopped responding to standard treatments. The main goal is to find the safest dose of the new combin…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo aims to tackle tough breast cancer in patients with metabolic issues
Disease control Recruiting nowThis phase 2 trial tests whether adding the experimental drug evexomostat (SDX-7320) to standard chemotherapy (eribulin) works better than chemotherapy alone for people with metastatic triple-negative breast cancer who also have metabolic dysfunction (like insulin resistance). Th…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study is testing two drugs together — alpelisib and pembrolizumab — in people with metastatic breast cancer or melanoma that has spread to the brain or other organs. The main goal is to find a safe dose and see what side effects occur. Up to 50 adults whose cance…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy aims to outsmart hard-to-treat breast cancer
Disease control Recruiting nowThis early-stage trial tests whether giving the drug bortezomib first can make metastatic triple-negative breast cancer more sensitive to two other drugs (pembrolizumab and cisplatin). About 20 women with advanced breast cancer that has already been treated with standard chemothe…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could a simple capsule beat chemo fatigue? new trial aims to find out
Symptom relief Recruiting nowThis Phase 3 trial tests whether Nuvastatic 300 mg capsules can reduce the crushing fatigue that often comes with chemotherapy. About 250 women with metastatic triple-negative breast cancer will take either the supplement or a placebo three times daily for 60 days while continuin…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Natureceuticals Sdn Bhd • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Scientists hunt for clues to better treat aggressive breast cancer
Knowledge-focused Recruiting nowThis study is for people with metastatic triple-negative breast cancer who are already receiving the drug sacituzumab govitecan as part of their routine care. Researchers want to see how well the drug works in everyday practice and find biological markers (biomarkers) that predic…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Sponsor: Regina Elena Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC